← All trials
NCT00716391
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 7, 2008
- Primary completion
- Jul 18, 2017
- Completion date
- Dec 31, 2017
- First posted
- Jul 16, 2008
- Last posted
- May 24, 2019
- Enrollment
- 519
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Grupo Español de Tratamiento de Tumores de Cabeza y CuelloLead sponsor
- Universidad Complutense de MadridOverall official - principal investigator
- University of SalamancaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.